Los Angeles, CA – October 12, 2018 – Today, ÉlpisÉremo Inc. and Esai Morales announced they have joined forces to accelerate bleeding-edge technologies in an effort to develop a cure for neurodegenerative diseases, including; Alzheimer’s Disease, Parkinson’s, and traumatic brain injury. Alzheimer’s dementia alone is a global epidemic presently affecting 50 million people worldwide and 5.7 million Americans.
OmGeneum will harness ÉlpisÉremo’s groundbreaking “MINaR” technology platform to combat these incurable diseases. MINaR precisely targets and modulates the body’s own tissue-specific, cell-signaling pathways to induce pluripotent gene and protein expression in targeted, tissue-resident stem cells. These pathways are the key biological mechanisms involved in human tissue regeneration, repair, and healing, including neurogenesis, Cardiogenesis, skeletal myogenesis, osteogenesis, chondrogenesis, Vasculogenesis, hepatogenesis, and organogenesis.
“As a grateful son, I would do anything to help my mother regain her mind and memories,” declared Esai Morales. “So much of who I am is due to her. Every piece of conventional medical advice I receive tries to convince me to accept a tragic outcome. My mother would never accept this prognosis for me; I will not accept it of her. I am very excited to join forces with ElpisEremo and their world-class team of scientists and cutting-edge technology that offers hope to all those suffering from degenerative diseases. I am dedicated to helping make Elpis accessible to all. If it can help my beloved Mother, it can help anyone.”
“We are planning to begin clinical trials in 2019. ElpisEremo’s is pioneering a precision regenerative technology that literally makes the human body a regenerative protein bioreactor which we believe can help us overcome the tremendous challenges of regenerating and restoring neurologic function in the severely diseased brains,” said James Ryan, CEO of ElpisEremo.
“We are now able to precisely target tissue-resident stem cells without the need for cell/tissue transplantation or mRNA drugs. This new approach has remarkable implications for self-healing,” said Dr. Carlo Ventura, ÉlpisÉremo’s CSO “We can modulate the expression of regenerative genes and proteins without gene transfer technologies or the use of cumbersome synthetic chemistry. The modulation of such “epigenetic symphony” is our strategy to cope with these devastating degenerative disorders, including neural and cardiac degenerative diseases. This new approach has remarkable implications, as we are now seeing stem cell biology with the eyes of Physics, developing a Regenerative/Precision medicine afforded through the stimulation of the natural ability of tissues for self-healing.”
ÉlpisÉremo is a bioengineering, a regenerative biotechnology company, co-founded by a world-class team of scientists, determined to accelerate the development of the next-generation regenerative technology. To this end, ÉlpisÉremo’s team of scientists harnessed novel, molecular signature codes to develop the MINaR [Multifrequency Induced Nanoarchitectonics Reprogramming] platform which precisely targets tissue-restricted cell pathways, activating transcription factors and specific gene/protein expression in the cells of the diseased target organ to synthesize potent regenerative/therapeutic proteins.
OmGeneum consists of an interdisciplinary team of stem cell pioneers from Harvard University, Carnegie Melon University, Bologna University, in Italy, and UCLA, and includes a Nobel laureate, a former U.S. Congressman, and long-time social justice activist Esai Morales. The group is dedicated to accelerating technology breakthroughs to conquer devastating neurodegenerative diseases that cause such severe suffering.
For more information, visit: https://www.omgeneum.com/
Public Relations: firstname.lastname@example.org
Company Name: Omgeneum Inc.
Contact Person: Mark Andresson
Email: Send Email
Phone: 1 786 352 8723
Address:65 Ponce de Leon Ave. STE 201
City: San Juan 00917
Country: Puerto Rico